Benzonatate for Cough in Pneumonia
Benzonatate is appropriate for symptomatic relief of cough in pneumonia patients, as it is FDA-approved for cough suppression and acts peripherally without affecting respiratory drive. 1
Rationale for Use
Benzonatate is a peripherally-acting antitussive that anesthetizes stretch receptors in the respiratory passages, lungs, and pleura, thereby reducing the cough reflex at its source 1. It begins working within 15-20 minutes and lasts 3-8 hours, with no inhibitory effect on the respiratory center at recommended doses 1.
Key Clinical Considerations:
Dosing: Adults should take 100-200 mg three times daily as needed, up to 600 mg daily in divided doses. Capsules must be swallowed whole—never broken, chewed, dissolved, cut, or crushed 1. This is critical as breaking the capsule can cause local anesthesia of the oral mucosa and potential toxicity.
Safety Profile: While benzonatate can cause serious toxicity in overdose (seizures, dysrhythmias, death), unintentional therapeutic exposures rarely result in clinically significant adverse effects 2. Intentional overdoses carry substantially higher risk 2.
Evidence Limitations
The 2006 ACCP guidelines on cough suppressants do not specifically address benzonatate, focusing instead on codeine, dextromethorphan, and ipratropium bromide for various respiratory conditions 3. However, these guidelines primarily evaluated chronic bronchitis and upper respiratory infections—not pneumonia specifically.
The 2019 CHEST guideline on acute cough due to suspected pneumonia does not make specific recommendations for or against symptomatic cough therapies 4. This reflects the general lack of high-quality evidence for antitussive agents in pneumonia.
Important caveat: A 2023 systematic review found substantial limitations in benzonatate's evidence base, noting that initial clinical studies used very small populations and that its approval was founded on evidence that "would not stand up to current regulatory review" 5. Despite this, benzonatate remains widely prescribed and FDA-approved.
Clinical Algorithm
For pneumonia patients with bothersome cough:
- If cough is nonproductive and interfering with sleep/quality of life: Benzonatate is reasonable at standard dosing 1
- If cough is productive: Focus on treating the underlying pneumonia with appropriate antibiotics; avoid aggressive cough suppression as productive cough aids clearance
- Monitor for: Adequate capsule swallowing (especially in elderly or those with dysphagia), signs of toxicity if accidental overdose occurs
- Duration: Use only as needed for symptomatic relief during acute illness
The primary treatment remains appropriate antimicrobial therapy for the pneumonia itself 4, 6. Benzonatate serves only as adjunctive symptomatic therapy and should not delay or replace definitive pneumonia treatment.